76:
horses). The applicability of GH and IGF-1 treatments are currently being pursued by many pharmaceutical companies for a variety of human conditions. Based on the success of drug treatments, over time, Braasch will pursue additional applications and intellectual property for their vaccination approach (e.g. development of
75:
For human applications, Braasch
Biotech is focused on human obesity and Type 2 diabetes applications, along with Growth Hormone deficiencies and IGF-1 disorders. In the veterinary field, Braasch has developed vaccines to increase livestock productivity and reduce obesity in pets (dogs, cats, and
66:
Braasch's
Somatostatin vaccine technology allows the immune system to temporarily reduce, but not eliminate, the mostly inhibitory actions of Somatostatin. The vaccination effect causes more Growth Hormone to be released, which in turn stimulates the release of IGF-1 from the liver. This hormone
42:
In addition to developing and testing its
Somatostatin vaccine technology in a variety of species and for different metabolic conditions, the company has also expanded its worldwide intellectual property positions by multiple filings and anticipates several additional filings to support their
168:
172:
143:
260:
250:
186:
39:
In 2008, Braasch
Biotech LLC was incorporated in the State of South Dakota. Their total focus was on developing Somatostatin vaccines and related technology.
255:
67:
cascade can help address issues relating to obesity and Type 2 diabetes, since growth hormone deficiencies can lead to increased risk for those conditions.
97:
245:
60:
118:
23:
products for the human and veterinary healthcare markets. Specifically, Braasch has developed the world's first anti-
207:
77:
51:
Somatostatin (also known as Growth
Hormone Inhibiting Hormone) is the main regulator for the release of
144:"Braasch Biotech Granted Novel Patent for Somatostatin Vaccines in High-Value Therapeutic Markets"
55:(GH) from the pituitary gland, which leads to several body functions including an increase of
27:
vaccine. They are also researching applications for Growth
Hormone Deficiency and Type 2
52:
156:
239:
19:
is a privately held company that specializes in the development of biopharmaceutical
187:"Braasch Biotech Therapeutic Vaccines Profiled in International Marketing Report"
122:
63:, also a hypothalamus hormone, which controls the release of Growth Hormone.
59:(Insulin-like Growth Factor 1) levels. Somatostatin inhibits the actions of
28:
24:
20:
56:
231:
98:"World's First Anti-Obesity Vaccine Developed in South Dakota"
208:"Blockbuster Vaccines of the Future | FiercePharma"
157:
http://www.medicalnewstoday.com/articles/162473.php
8:
261:Pharmaceutical companies established in 2008
251:Biotechnology companies established in 2008
89:
7:
256:2008 establishments in South Dakota
14:
119:"Braasch Biotech LLC - About Us"
61:Growth Hormone-Releasing Hormone
246:Companies based in South Dakota
169:"United States Patent: 7722881"
1:
100:. Business Wire. 2010-11-09
277:
71:Research and development
78:myocardial infarction
210:. Fiercevaccines.com
17:Braasch Biotech LLC
189:. Onlineprnews.com
268:
219:
218:
216:
215:
204:
198:
197:
195:
194:
183:
177:
176:
175:on 16 July 2012.
171:. Archived from
165:
159:
154:
148:
147:
140:
134:
133:
131:
130:
121:. Archived from
115:
109:
108:
106:
105:
94:
276:
275:
271:
270:
269:
267:
266:
265:
236:
235:
228:
223:
222:
213:
211:
206:
205:
201:
192:
190:
185:
184:
180:
167:
166:
162:
155:
151:
142:
141:
137:
128:
126:
117:
116:
112:
103:
101:
96:
95:
91:
86:
73:
49:
37:
12:
11:
5:
274:
272:
264:
263:
258:
253:
248:
238:
237:
234:
233:
227:
226:External links
224:
221:
220:
199:
178:
160:
149:
135:
110:
88:
87:
85:
82:
72:
69:
53:Growth Hormone
48:
45:
36:
33:
13:
10:
9:
6:
4:
3:
2:
273:
262:
259:
257:
254:
252:
249:
247:
244:
243:
241:
232:
230:
229:
225:
209:
203:
200:
188:
182:
179:
174:
170:
164:
161:
158:
153:
150:
145:
139:
136:
125:on 2011-04-06
124:
120:
114:
111:
99:
93:
90:
83:
81:
80:treatments).
79:
70:
68:
64:
62:
58:
54:
46:
44:
40:
34:
32:
30:
26:
22:
18:
212:. Retrieved
202:
191:. Retrieved
181:
173:the original
163:
152:
146:. June 2010.
138:
127:. Retrieved
123:the original
113:
102:. Retrieved
92:
74:
65:
50:
43:technology.
41:
38:
16:
15:
240:Categories
214:2019-10-17
193:2019-10-17
129:2011-03-15
104:2019-10-17
84:References
47:Technology
31:markets.
29:diabetes
35:History
25:obesity
21:vaccine
57:IGF-1
242::
217:.
196:.
132:.
107:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.